Business Description
Founded in 2019 and headquartered in Seoul, South Korea, Kanaph Therapeutics is a drug development company operating across South Korea and the United States. The company is building a portfolio of treatments for cancer and eye disease, with several candidates already in or past preclinical testing, including one drug currently in Phase 1 clinical trials. Its work spans multiple scientific approaches, such as bispecific antibodies, protein-based therapies, and small-molecule compounds, targeting conditions like solid tumors, lung cancer, colorectal cancer, and wet macular degeneration.
